These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11340371)

  • 1. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Mavroudis D; Kalbakis K; Kotsakis A; Vardakis N; Koukourakis M; Romanos J; Georgoulias V
    Oncology; 2001; 60(3):207-13. PubMed ID: 11340371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
    Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
    Vamvakas L; Kakolyris S; Kouroussis C; Kandilis K; Mavroudis D; Ziras N; Androulakis N; Kalbakis K; Sarra E; Souglakos J; Georgoulias V;
    Am J Clin Oncol; 2002 Feb; 25(1):65-70. PubMed ID: 11823700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
    Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
    J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
    Kambe M; Kikuchi H; Gamo M; Yoshioka T; Ohashi Y; Kanamaru R
    Int J Clin Oncol; 2012 Apr; 17(2):150-4. PubMed ID: 21786211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
    Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
    Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E;
    Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
    Goldberg RM; Kaufmann SH; Atherton P; Sloan JA; Adjei AA; Pitot HC; Alberts SR; Rubin J; Miller LL; Erlichman C
    Ann Oncol; 2002 Oct; 13(10):1674-80. PubMed ID: 12377659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
    Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
    Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
    Ficorella C; Ricevuto E; Morelli MF; Morese R; Cannita K; Cianci G; Porzio G; Di Rocco ZC; De Galitiis F; De Tursi M; Tinari N; Iacobelli S; Marchetti P
    Oncol Rep; 2006 May; 15(5):1345-50. PubMed ID: 16596209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
    Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
    J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
    Ducreux M; Ychou M; Seitz JF; Bonnay M; Bexon A; Armand JP; Mahjoubi M; Méry-Mignard D; Rougier P
    J Clin Oncol; 1999 Sep; 17(9):2901-8. PubMed ID: 10561369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
    Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.